{"request_id":"352b60ca3ecda804f410b42ab44b6aa4","results":{"ticker":"VRTX","name":"Vertex Pharmaceuticals Inc","market":"stocks","locale":"us","primary_exchange":"XNAS","type":"CS","active":true,"currency_name":"usd","cik":"0000875320","composite_figi":"BBG000C1S2X2","share_class_figi":"BBG001S68LJ8","market_cap":89773119501.45,"phone_number":"(617) 341-6393","address":{"address1":"50 NORTHERN AVENUE","city":"BOSTON","state":"MA","postal_code":"02210"},"description":"Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.","sic_code":"2834","sic_description":"PHARMACEUTICAL PREPARATIONS","ticker_root":"VRTX","homepage_url":"https://www.vrtx.com","total_employees":4800,"list_date":"1991-07-31","share_class_shares_outstanding":258100000,"weighted_shares_outstanding":258094815,"round_lot":100},"status":"OK"}
